Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

Lisa KobrynskiDepartment of Pediatrics, Emory University, Atlanta, GA, USAAbstract: Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Kobrynski L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/5352b791509b4c489e7611f4de1324f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5352b791509b4c489e7611f4de1324f9
record_format	dspace
spelling	oai:doaj.org-article:5352b791509b4c489e7611f4de1324f92021-12-02T08:02:17ZSubcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases1177-54751177-5491https://doaj.org/article/5352b791509b4c489e7611f4de1324f92012-08-01T00:00:00Zhttp://www.dovepress.com/subcutaneous-immunoglobulin-therapy-a-new-option-for-patients-with-pri-a10803https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Lisa KobrynskiDepartment of Pediatrics, Emory University, Atlanta, GA, USAAbstract: Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3&ndash;4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.Keywords: primary immunodeficiency diseases, subcutaneous immunoglobulin, immunoglobulin GKobrynski LDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 277-287 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Kobrynski L Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
description	Lisa KobrynskiDepartment of Pediatrics, Emory University, Atlanta, GA, USAAbstract: Since the 1950s, replacement of immunoglobulin G using human immunoglobulin has been the standard treatment for primary immunodeficiency diseases with defects in antibody production. These patients suffer from recurrent and severe infections, which cause lung damage and shorten their life span. Immunoglobulins given intravenously (IVIG) every 3&ndash;4 weeks are effective in preventing serious bacterial infections and improving the quality of life for treated patients. Administration of immunoglobulin subcutaneously (SCIG) is equally effective in preventing infections and has a lower incidence of serious adverse effects compared to IVIG. The tolerability and acceptability of SCIG has been demonstrated in numerous studies showing improvements in quality of life and a preference for subcutaneous immunoglobulin therapy in patients with antibody deficiencies.Keywords: primary immunodeficiency diseases, subcutaneous immunoglobulin, immunoglobulin G
format	article
author	Kobrynski L
author_facet	Kobrynski L
author_sort	Kobrynski L
title	Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
title_short	Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
title_full	Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
title_fullStr	Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
title_full_unstemmed	Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
title_sort	subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/5352b791509b4c489e7611f4de1324f9
work_keys_str_mv	AT kobrynskil subcutaneousimmunoglobulintherapyanewoptionforpatientswithprimaryimmunodeficiencydiseases
_version_	1718398661042372608

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

Ejemplares similares